Brind.

Entities / Infrastructure

TTR.

Infrastructure

Seen in 16 reportsLast reported Sep 22

Reports this week: 0
Active events: 0
Connections: 15

What's happening

Reports per dayLast 90 days

90 days agoDrag either end to show only events that began in that periodToday

One to three months ago

TTR franchise is driving significant revenue and is listed on the electronic stock exchange.

Some support1 report

Gone quiet

No new reports in 90+ days

BridgeBio is seeking Accelerated Approval from the FDA for a treatment that utilizes increased TTR stabilization, showing positive results for CVH events.

Some support2 reports

Around TTR this week

News at the entities that move TTR most

Hoffmann-La Roche Transactional
Zymeworks and Hoffmann-La Roche announced a collaboration agreement for the development of ZW209.

Moves TTR
Fri 12:32
Novo Nordisk Operational
Novo Nordisk and Astellas Pharma are noted as large-cap healthcare companies, with Novo Nordisk reporting higher revenue and earnings.

Moves TTR
Fri 18:20
Bristol-Myers Squibb Operational
University of Hyderabad is hosting a drug discovery program featuring scientists from Pfizer and Bristol-Myers Squibb in Hyderabad.

Moves TTR
Fri 16:43
Nasdaq Structural
Wall Street indices, including the S&P 500 and Dow Jones, closed lower on January 1, 2025.

Moves TTR
02:04
Munich Shared context
Rekha Rao was elected a fellow of the Society of Rheology in Munich, Germany.

Moves TTR
Fri 18:07

Connections

The 6 strongest of 15, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.

Hoffmann-La Roche Transactional

Hoffmann-La Roche is currently evaluating TTR's technology/product, prasinezumab, for potential application in Parkinson's disease.

Some supportAug 6

TTR → Hoffmann-La Roche
Hoffmann-La Roche → TTR
Nasdaq Structural

TTR functions as an infrastructure company whose business operations are dependent on the existence and functionality of the Nasdaq market platform.

Some supportJul 30

TTR → Nasdaq
Nasdaq → TTR
Munich Shared context

TTR's findings are discussed and presented within the context of the European Society of Cardiology Congress held in Munich.

Some supportAug 30

TTR → Munich
Munich → TTR
Ionis Pharmaceuticals Structural

Ionis Pharmaceuticals is focused on developing therapeutic agents that specifically target the TTR protein.

Some supportSep 22

TTR → Ionis Pharmaceuticals
Ionis Pharmaceuticals → TTR
Novo Nordisk Operational

Novo Nordisk is actively evaluating therapeutic strategies targeting the TTR protein associated with ATTR amyloidosis.

Some supportAug 6

TTR → Novo Nordisk
Novo Nordisk → TTR
Bristol-Myers Squibb Operational

Bristol-Myers Squibb is evaluating TTR's drug candidate, moponetug, for Alzheimer's disease.

Some supportAug 6

TTR → Bristol-Myers Squibb
Bristol-Myers Squibb → TTR

History

Events by the month they began

July 2026

1 event

Jul 28, 2026TTR franchise is driving significant revenue and is listed on the electronic stock exchange.

June 2026

1 event

Jun 7, 2026BridgeBio is seeking Accelerated Approval from the FDA for a treatment that utilizes increased TTR stabilization, showing positive results for CVH events.